12/1
08:10 am
cocp
Cocrystal Pharma to Present at the Noble Capital Markets' 21st Emerging Growth Equity Conference [Yahoo! Finance]
Low
Report
Cocrystal Pharma to Present at the Noble Capital Markets' 21st Emerging Growth Equity Conference [Yahoo! Finance]
12/1
08:00 am
cocp
Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference
Low
Report
Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference
11/19
01:17 pm
cocp
Cocrystal Pharma (NASDAQ:COCP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Cocrystal Pharma (NASDAQ:COCP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/14
07:08 pm
cocp
Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs [Yahoo! Finance]
Low
Report
Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs [Yahoo! Finance]
11/14
08:36 am
cocp
Cocrystal Pharma GAAP EPS of -$0.19 beats by $0.02 [Seeking Alpha]
Low
Report
Cocrystal Pharma GAAP EPS of -$0.19 beats by $0.02 [Seeking Alpha]
11/14
08:00 am
cocp
Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Neutral
Report
Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
10/30
08:00 am
cocp
Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules
Medium
Report
Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules
10/27
08:00 am
cocp
Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program
Medium
Report
Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program
10/2
08:05 am
cocp
Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference [Yahoo! Finance]
Medium
Report
Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference [Yahoo! Finance]
10/2
08:00 am
cocp
Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference
Medium
Report
Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference
9/19
04:51 pm
cocp
Cocrystal Pharma files to sell 5.74M shares of common stock for holders [Seeking Alpha]
Low
Report
Cocrystal Pharma files to sell 5.74M shares of common stock for holders [Seeking Alpha]
9/15
04:30 pm
cocp
Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Medium
Report
Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
9/12
09:50 am
cocp
Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules [Yahoo! Finance]
Medium
Report
Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules [Yahoo! Finance]
9/12
09:43 am
cocp
Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
High
Report
Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
9/12
08:25 am
cocp
Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference [Yahoo! Finance]
High
Report
Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference [Yahoo! Finance]
9/12
08:00 am
cocp
Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference
Medium
Report
Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference
9/8
08:00 am
cocp
Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment
High
Report
Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment